We demonstrated that ip administration of “Neo-Islets” (NIs; co-aggregation of allogeneic, culture-expanded Islet cells (ICs) with Adipose derived Stem Cells (ASCs)), resulted in their omental engraftment in immune-competent, diabetic NOD mice. This achieved durable euglyciemia without immunosuppression, and with physiologic delivery of insulin and other islet hormones (SCTM 2017;6:1631). We are conducting an FDA guided pilot study (INAD 012-1248) of this technology in spontaneously T1DM pet dogs (see abstract this session). ICs and ASCs are known to be subject to gluco- and lipotoxicity. We undertook this study to determine whether the Hypertriglyceridemic (HTG) and/or DM milieu has an adverse effect (lipotoxic and/or glucotoxic) on dog ASCs and ICs and NIs.

Accordingly, serum was collected from HTG, DM dogs enrolled in INAD 012-776 before and after control of HTG and glucose levels, and from non-DM HTG dogs. These sera were added separately (10%) to DMEM at either 5mM or 17mM glucose for dog ASC and IC cultures. Growth rates and gene expression profiles were assessed.

Serum from DM (glucose 123-742 mg/dL) dogs with untreated HTG (range 656-1248 mg/dL; normal 20-248 mg/dL) killed ICs at either 5 or 17 mM glucose, and failed to support the expansion of ASCs in 17mM glucose. For ASCs grown in 17mM glucose expression of IL-6 and IGF-1 were downregulated. In contrast, sera from DM dogs with controlled HTG (range 146-656 mg/dL), and serum from HTG (range 742-1114 mg/dL), non-DM dogs supported the growth of both cell types in either medium with no changes in gene expression. In agreement with these in vitro results, an uncontrolled NI-treated study dog failed to respond to therapy, while HTG and glucose-controlled dogs have shown up to 50% reduced need for insulin 12 months post therapy.

Conclusion: These data demonstrate the need for optimal glucose and lipid control to prevent destruction of the NI cells when treating DM.


A. Gooch: Board Member; Self; SymbioCellTech. S.S. Chowdhury: Employee; Self; SymbioCellTech. C. Westenfelder: Consultant; Self; SymbioCellTech.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.